Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, +6

Oncotarget

UrologyGenitourinary CancerMedicinePharmacologyPathology +12

Response and Tolerability of a Single Dose of¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis

Kambiz Rahbar, Matthias Schmidt, Alexander Heinzel, +5

Journal of Nuclear Medicine

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Hojjat Ahmadzadehfar, Simone Wegen, Anna Yordanova, +7

European Journal of Nuclear Medicine and Molecular Imaging

UrologyRadiologyRadioligand TherapyGenitourinary CancerMedicine +5

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival

Kambiz Rahbar, Martin Boegemann, Anna Yordanova, +4

European Journal of Nuclear Medicine and Molecular Imaging

UrologyGenitourinary CancerMedicinePharmacologyRetrospective Analysis +8

The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer

Anna Yordanova, Anja Becker, Elisabeth Eppard, +5

European Journal of Nuclear Medicine and Molecular Imaging

UrologySurgical OncologyRadioligand TherapyRenal FunctionGenitourinary Cancer +8

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617

Justin Ferdinandus, Elisabeth Eppard, Florian Gaertner, +7

Journal of Nuclear Medicine

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer

Anna Yordanova, Paula Linden, Stefan Hauser, +6

European Journal of Nuclear Medicine and Molecular Imaging

Metastatic Prostate CancerUrologyGenitourinary CancerMedicineCancer Management +4

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy

Hojjat Ahmadzadehfar, Stephan Schlolaut, Rolf Fimmers, +7

Oncotarget

Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer

Kambiz Rahbar, Martin Bögeman, Anna Yordanova, +4

European Journal of Nuclear Medicine and Molecular Imaging

UrologyGenitourinary CancerMedicineCancer TreatmentProstatic Disease +3

Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour

Anna Yordanova, Karin Mayer, Peter Brossart, +4

European Journal of Nuclear Medicine and Molecular Imaging

Malignant DiseaseMedicineNeuroendocrine DisorderPathologyMultiple Repeated Cycles +8